Wnt signaling in triple negative breast cancer is associated with metastasis

[1]  B. Leyland-Jones,et al.  Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner , 2013, PloS one.

[2]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[3]  Francisco M. De La Vega,et al.  Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities , 2012, Molecular Cancer Therapeutics.

[4]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[5]  Ganesh Bagler,et al.  An Approach for the Identification of Targets Specific to Bone Metastasis Using Cancer Genes Interactome and Gene Ontology Analysis , 2011, PloS one.

[6]  Matthew J. Ellis,et al.  Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy , 2011, International journal of breast cancer.

[7]  Gillian H. Little,et al.  Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2 , 2011, Breast Cancer Research.

[8]  B. Leyland-Jones,et al.  Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform , 2011, British Journal of Cancer.

[9]  Kornelia Polyak,et al.  Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.

[10]  N. Bertos,et al.  Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.

[11]  J. Reis-Filho,et al.  β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation , 2011, Modern Pathology.

[12]  S. Moulder.  Does the PI3K pathway play a role in basal breast cancer? , 2010, Clinical breast cancer.

[13]  Daniel Birnbaum,et al.  Genome profiling of ERBB2-amplified breast cancers , 2010, BMC Cancer.

[14]  O. Olopade,et al.  Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .

[15]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[16]  L. Carey.  Directed therapy of subtypes of triple-negative breast cancer. , 2010, The oncologist.

[17]  Sarah A. Pendergrass,et al.  A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response , 2009, PloS one.

[18]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[19]  Jie J. Zheng,et al.  Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled. , 2009, Angewandte Chemie.

[20]  R. Cardiff,et al.  Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.

[21]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[22]  Marc Ladanyi,et al.  WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis , 2009, Cell.

[23]  Charles M Perou,et al.  A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. , 2009, Cancer research.

[24]  M. Bloomston,et al.  Thiazolidinediones downregulate Wnt/beta-catenin signaling via multiple mechanisms in breast cancer cells. , 2009, The Journal of surgical research.

[25]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[26]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[27]  I. Gérin,et al.  On the Role of FOX Transcription Factors in Adipocyte Differentiation and Insulin-stimulated Glucose Uptake* , 2009, Journal of Biological Chemistry.

[28]  Luke H. Hoeppner,et al.  Wnt signaling as a therapeutic target for bone diseases , 2009, Expert opinion on therapeutic targets.

[29]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Wenyan Lu,et al.  Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. , 2009, European journal of pharmacology.

[31]  A. Ashworth,et al.  The genomic profile of HER2‐amplified breast cancers: the influence of ER status , 2008, The Journal of pathology.

[32]  R. Nusse,et al.  Wnt signaling mediates self-organization and axis formation in embryoid bodies. , 2008, Cell stem cell.

[33]  T. Yoneda,et al.  Breast cancer‐derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases , 2008, International journal of cancer.

[34]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[35]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[36]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[37]  Wancai Yang,et al.  Sulindac suppresses beta-catenin expression in human cancer cells. , 2008, European Journal of Pharmacology.

[38]  R. Parsons,et al.  The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. , 2008, Cancer research.

[39]  Brian Leyland-Jones,et al.  Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. , 2008, BioTechniques.

[40]  Tara L. Naylor,et al.  Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer , 2007, Clinical Cancer Research.

[41]  B. Cieply,et al.  siRNA-Mediated β-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival* , 2007 .

[42]  Charles M Perou,et al.  EGFR associated expression profiles vary with breast tumor subtype , 2007, BMC Genomics.

[43]  H. Ishwaran,et al.  Lung metastasis genes couple breast tumor size and metastatic spread , 2007, Proceedings of the National Academy of Sciences.

[44]  B. Cieply,et al.  SiRNA‐Mediated β‐catenin Knockdown in Human Hepatoma Cells Results in Their Decreased Growth and Survival , 2007, Neoplasia.

[45]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Mu Wang,et al.  CSK Controls Retinoic Acid Receptor (RAR) Signaling: a RAR-c-SRC Signaling Axis Is Required for Neuritogenic Differentiation , 2007, Molecular and Cellular Biology.

[47]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[48]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[49]  O. MacDougald,et al.  Regulation of bone mass by Wnt signaling. , 2006, The Journal of clinical investigation.

[50]  P. Genever,et al.  Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro , 2006, Journal of Cell Science.

[51]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[52]  Vincent J Carey,et al.  Bioconductor: an open source framework for bioinformatics and computational biology. , 2006, Methods in enzymology.

[53]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[54]  S. Ishii,et al.  The Wnt-NLK signaling pathway inhibits A-Myb activity by inhibiting the association with coactivator CBP and methylating histone H3. , 2005, Molecular biology of the cell.

[55]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[56]  T. Guise,et al.  Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy , 2005, Journal of Mammary Gland Biology and Neoplasia.

[57]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[58]  S. Lakhani,et al.  Molecular evolution of breast cancer , 2005, The Journal of pathology.

[59]  Jan Kitajewski,et al.  Wnt/beta-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. , 2005, Angiogenesis.

[60]  Jan Kitajewski,et al.  Wnt/β-Catenin Signaling Induces Proliferation, Survival and Interleukin-8 in Human Endothelial Cells , 2005, Angiogenesis.

[61]  Barbara J. Trask,et al.  Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes , 2004, Cancer Research.

[62]  Jian-Bing Fan,et al.  A versatile assay for high-throughput gene expression profiling on universal array matrices. , 2004, Genome research.

[63]  P. V. van Diest,et al.  Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry , 2004, British Journal of Cancer.

[64]  Paul S Rennie,et al.  Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis , 2003, Oncogene.

[65]  Hans Clevers,et al.  Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. , 2002, Cancer research.

[66]  Jonathan R Pollack,et al.  A transcriptional response to Wnt protein in human embryonic carcinoma cells , 2002, BMC Developmental Biology.

[67]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[69]  Minoru Kanehisa,et al.  The KEGG database. , 2002, Novartis Foundation symposium.

[70]  B. Boman,et al.  Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. , 2001, Cancer research.

[71]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[73]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[74]  Thomas Kirchner,et al.  β-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer , 1999 .

[75]  W F Bodmer,et al.  Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  H Clevers,et al.  Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. , 1999, The American journal of pathology.

[77]  K. Kinzler,et al.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. , 1999, Cell.

[78]  T. Brabletz,et al.  beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. , 1999, The American journal of pathology.

[79]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[80]  O. Jänne,et al.  CREB-binding protein in androgen receptor-mediated signaling. , 1998, Proceedings of the National Academy of Sciences of the United States of America.